Peptide-based blood coagulant (Haemostatix)

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePeptide-based blood coagulant (Haemostatix)

Drug Alias NamePeproStat LiquidPeproStatHaemostat topical - HaemostatixPeptide-based antihaemorrhagic - HaemostatixHaemostasis therapeutic - Haemostatix

ClassificationBiologics > Protein drugs > Recombinant protein

Mechanisms of ActionFibrinogen modulatorsFibrin stimulants

TargetsFibrinogenFibrin

Therapy Area/IndicationsHemorrhage

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBosnia and HerzegovinaPolandSerbia +[5]

CombinationsNo

Global Highest StatusPending (Phase 2 Clinical)

Highest Status in ChinaN/A

Originator CompaniesHaemostatix Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesHaemostatix Ltd

Active IndicationsN/A

Inactive IndicationsHemorrhage

Other Information

ATC CodeN/A